Bluejay begins phase 3 trial of brelovitug for hepatitis D - PharmaTimes First patient enrolled in AZURE-2 study comparing brelovitug to Hepcludex

#Bluejay #BluejayTherapeutics #phase3trial #brelovitug #BJT778 #hepatitisD #AZURE2study #CHD #hepatitisDvirus #cirrhosis #livercancer #viralhepatitis #liverdisease #BreakthroughTherapydesignation #FDA #PRIMEdesignation #Orphanstatus #OrphanDrug #EMA
pharmatimes.com/news/bluejay...